Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

Global market grows at 6.3% CAGR through 2033 as demand rises for safer, targeted chemotherapy treatments worldwide.

Annual meeting moves to the New York Marriott Marquis on October 13-16, marking a new chapter and providing a refreshed ...

C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading. As of ...

Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...

Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.

The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.

Continued treatment with Briumvi provided sustained clinical benefits to patients with relapsing MS, particularly when ...

Colon cancer survivor Vivian Chee has had three lung surgeries since 2021 but continues to keep fit. Read more at straitstimes.com. Read more at straitstimes.com.

His breakout role came in 2006 as the handsome Dr. Mark Sloan, nicknamed McSteamy, the head of plastic surgery at a Seattle hospital. He died 10 months after announcing his A.L.S. diagnosis.